Benzodiazepines and Alcohol Are Associated with Cases of Fatal Buprenorphine Poisoning

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 2011 Sep 20

PMID 21927835

Citations 34

Authors

Margareeta Hakkinen

Terhi Launiainen

Erkki Vuori

Ilkka Ojanpera

Affiliations

Soon will be listed here.

Abstract

Background: Although buprenorphine therapy has proved to be successful in opioid maintenance treatments, the drug is also widely abused in many countries by intravenous injection or sniffing ("snorting"). In Finland, buprenorphine is the most important abused opioid causing fatal poisonings.

Purpose: To evaluate the drug and alcohol findings as well as the cause and manner of death in all buprenorphine-related post-mortem cases for the age group 14-44 years in Finland from 2000 to 2008.

Method: This was a retrospective analysis of data on opioid-associated deaths in the Finnish comprehensive postmortem toxicology database based on medico-legal autopsies, case background information and laboratory analyses.

Results: Buprenorphine was found in 29% of all 1,363 opioid-positive cases, and buprenorphine poisoning was the cause of death in 182 cases out of 391 buprenorphine-positive cases (47%). In these fatal poisonings, the blood buprenorphine/norbuprenorphine concentration ratio was significantly higher than in cases with other causes of death. The manner of death in buprenorphine poisonings that were almost exclusively accidental differed significantly from other buprenorphine-related cases, which also involved diseases and suicides. Death was immediate in 10% of fatal buprenorphine poisonings, was delayed, during sleep, in 52%, and followed an unknown course of events in 38%. In immediate poisonings, the median blood buprenorphine concentration (3.0 μg/l) was significantly higher than that in delayed poisonings (1.2 μg/l). In most buprenorphine poisonings (92%), no opioids other than buprenorphine were involved, but benzodiazepines and alcohol were found in 82 and 58% of cases, respectively. The median concentrations of opioids and benzodiazepines in buprenorphine poisonings were in the therapeutic range. Only one fatal poisoning was found in which neither alcohol nor drugs other than buprenorphine were found.

Conclusion: A fatal buprenorphine poisoning is typically accidental, and the average victim is a 27-year-old male addict. Circumstantial and environmental factors seem to be crucial in determining the outcome of the poisoning.

Citing Articles

Buprenorphine deaths confirmed by toxicology reveal a low proportion of opioid agonist treatment before death in Finland.

Mariottini C, Hakkinen M, Kriikku P, Ojanpera I Int J Legal Med. 2024; 138(6):2331-2338.

PMID: 38910139 PMC: 11490512. DOI: 10.1007/s00414-024-03273-5.

Brain PET imaging using C-flumazenil and C-buprenorphine does not support the hypothesis of a mutual interaction between buprenorphine and benzodiazepines at the neuroreceptor level.

Auvity S, Vodovar D, Goutal S, Cisternino S, Chevillard L, Soyer A J Cereb Blood Flow Metab. 2023; 44(3):449-458.

PMID: 38097513 PMC: 10870960. DOI: 10.1177/0271678X231221040.

EPD1504: a novel μ-opioid receptor partial agonist attenuates obsessive-compulsive disorder (OCD)-like behaviors.

Youngblood B, Medina J, Gehlert D, Schwartz N Front Psychiatry. 2023; 14:1170541.

PMID: 37457777 PMC: 10349350. DOI: 10.3389/fpsyt.2023.1170541.

Characterization of Unintentional Deaths Among Buprenorphine Users.

Dai Z, Limen G, Abate M, Kraner J, Mock A, Smith G J Stud Alcohol Drugs. 2023; 84(1):171-179.

PMID: 36799687 PMC: 9948141. DOI: 10.15288/jsad.22-00049.

Investigation of buprenorphine-related deaths using urinary metabolite concentrations.

Mariottini C, Kriikku P, Ojanpera I Drug Test Anal. 2022; 14(10):1696-1702.

PMID: 35834288 PMC: 9796430. DOI: 10.1002/dta.3347.

References

Caplehorn J, Drummer O . Fatal methadone toxicity: signs and circumstances, and the role of benzodiazepines. Aust N Z J Public Health. 2002; 26(4):358-62; discussion 362-3. DOI: 10.1111/j.1467-842x.2002.tb00185.x. View

Kintz P . A new series of 13 buprenorphine-related deaths. Clin Biochem. 2002; 35(7):513-6. DOI: 10.1016/s0009-9120(02)00304-1. View

Ojanpera I, Rasanen I, Vuori E . Automated quantitative screening for acidic and neutral drugs in whole blood by dual-column capillary gas chromatography. J Anal Toxicol. 1991; 15(4):204-8. DOI: 10.1093/jat/15.4.204. View

Jasinski D, Pevnick J, Griffith J . Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry. 1978; 35(4):501-16. DOI: 10.1001/archpsyc.1978.01770280111012. View

Elkader A, Sproule B . Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet. 2005; 44(7):661-80. DOI: 10.2165/00003088-200544070-00001. View

Pelander A, Ojanpera I, Laks S, Rasanen I, Vuori E . Toxicological screening with formula-based metabolite identification by liquid chromatography/time-of-flight mass spectrometry. Anal Chem. 2003; 75(21):5710-8. DOI: 10.1021/ac030162o. View

Pelander A, Ojanpera I, Sistonen J, Rasanen I, Vuori E . Screening for basic drugs in 2-mL urine samples by dual-plate overpressured layer chromatography and comparison with gas chromatography-mass spectrometry. J Anal Toxicol. 2003; 27(4):226-32. DOI: 10.1093/jat/27.4.226. View

Rasanen I, Kontinen I, Nokua J, Ojanpera I, Vuori E . Precise gas chromatography with retention time locking in comprehensive toxicological screening for drugs in blood. J Chromatogr B Analyt Technol Biomed Life Sci. 2003; 788(2):243-50. DOI: 10.1016/s1570-0232(02)01012-7. View

Rasanen I, Ojanpera I, Vuori E . Quantitative screening for benzodiazepines in blood by dual-column gas chromatography and comparison of the results with urine immunoassay. J Anal Toxicol. 2000; 24(1):46-53. DOI: 10.1093/jat/24.1.46. View

10.

Papworth D . High dose buprenorphine for postoperative analgesia. Anaesthesia. 1983; 38(2):163. DOI: 10.1111/j.1365-2044.1983.tb13941.x. View

11.

Nielsen S, Dietze P, Lee N, Dunlop A, Taylor D . Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment. Addiction. 2007; 102(4):616-22. DOI: 10.1111/j.1360-0443.2006.01731.x. View

12.

Kobayashi K, Yamamoto T, Chiba K, Tani M, Shimada N, Ishizaki T . Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. Drug Metab Dispos. 1998; 26(8):818-21. View

13.

Leander J . Buprenorphine is a potent kappa-opioid receptor antagonist in pigeons and mice. Eur J Pharmacol. 1988; 151(3):457-61. DOI: 10.1016/0014-2999(88)90543-2. View

14.

Martin W, EADES C, Thompson J, Huppler R, Gilbert P . The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther. 1976; 197(3):517-32. View

15.

Cowan A, Doxey J, Harry E . The animal pharmacology of buprenorphine, an oripavine analgesic agent. Br J Pharmacol. 1977; 60(4):547-54. PMC: 1667382. DOI: 10.1111/j.1476-5381.1977.tb07533.x. View

16.

Ojanpera S, Pelander A, Pelzing M, Krebs I, Vuori E, Ojanpera I . Isotopic pattern and accurate mass determination in urine drug screening by liquid chromatography/time-of-flight mass spectrometry. Rapid Commun Mass Spectrom. 2006; 20(7):1161-7. DOI: 10.1002/rcm.2429. View

17.

Launiainen T, Vuori E, Ojanpera I . Prevalence of adverse drug combinations in a large post-mortem toxicology database. Int J Legal Med. 2008; 123(2):109-15. DOI: 10.1007/s00414-008-0261-3. View

18.

Lewis J . Ring C-bridged derivatives of thebaine and oripavine. Adv Biochem Psychopharmacol. 1973; 8(0):123-36. View

19.

Selden T, Roman M, Druid H, Kronstrand R . LC-MS-MS analysis of buprenorphine and norbuprenorphine in whole blood from suspected drug users. Forensic Sci Int. 2011; 209(1-3):113-9. DOI: 10.1016/j.forsciint.2011.01.011. View

20.

Lintzeris N, Mitchell T, Bond A, Nestor L, Strang J . Pharmacodynamics of diazepam co-administered with methadone or buprenorphine under high dose conditions in opioid dependent patients. Drug Alcohol Depend. 2007; 91(2-3):187-94. DOI: 10.1016/j.drugalcdep.2007.05.019. View